Exploring the risk of infection events in patients with asthma receiving anti-IL-5 monoclonal antibodies: A rapid systematic review and a meta-analysis

Introduction: Benralizumab, mepolizumab, and reslizumab are novel monoclonal antibodies approved for asthma, targeting eosinophilic inflammation. Benralizumab is directed against IL-5 receptor (IL-5R), while mepolizumab and reslizumab are directed against IL-5. The three drugs cause a reduction in e...

Полное описание

Библиографические подробности

Главные авторы:	Riccardo Giossi, Arianna Pani, Jan Schroeder, Francesco Scaglione
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2024-01-01
Серии:	Heliyon
Предметы:	Benralizumab Mepolizumab Reslizumab IL-5 Infection Meta-analysis
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2405844023109339
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!